Regulatory FDA taps prior knowledge to expedite cell and gene therapy development BioSpaceA year of significant policy change at the FDA brought momentum and scrutiny into the new year.Gene Therapy PlatformRead full story pharminent June 3, 2026 (Last updated: June 3, 2026) BioSpace A year of significant policy change at the FDA brought momentum and scrutiny into the new year. Gene Therapy Platform Read full story Post navigation Previous: AbbVie receives EC approval for Aquipta to treat migraineNext: Travere beefs up rare kidney disease portfolio with up to $1.1B China deal Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026